Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Istituto di Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Istituto di Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy.
J Neuroimmunol. 2021 Apr 15;353:577525. doi: 10.1016/j.jneuroim.2021.577525. Epub 2021 Feb 20.
Tumour Necrosis Factor alpha (TNFα) blockers are common and effective treatments for several autoimmune diseases but can be associated with neuroinflammatory events. We describe the disease course of ten patients who developed CNS demyelinating events while exposed to TNFα blockers. We divided them into two groups: eight patients with Relapsing Multiple Sclerosis and two isolated optic neuritis. In our cohort, TNFα blockers-associated Multiple Sclerosis does not seem to be associated with a more aggressive course and can be managed with MS-specific DMTs, chosen considering the clinical course and the concomitant autoimmune disease. Our findings need confirmation in larger cohorts to further characterize the disease course of TNFα blockers-associated Multiple Sclerosis.
肿瘤坏死因子-α（TNFα）阻滞剂是治疗多种自身免疫性疾病的常用且有效的药物，但也可能与神经炎症事件相关。我们描述了 10 名接受 TNFα 阻滞剂治疗后发生中枢神经系统脱髓鞘事件的患者的疾病过程。我们将他们分为两组：8 名复发性多发性硬化症患者和 2 名孤立性视神经炎患者。在我们的队列中，TNFα 阻滞剂相关的多发性硬化症似乎与更具侵袭性的病程无关，并且可以使用多发性硬化症特异性疾病修正治疗药物（DMTs）进行治疗，具体药物的选择需要考虑临床病程和同时存在的自身免疫性疾病。我们的发现需要在更大的队列中进一步证实，以进一步描述 TNFα 阻滞剂相关多发性硬化症的疾病病程。
